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Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is caused by mutations in TYMP, the
gene encoding the enzyme thymidine phosphorylase (TP). TP dysfunction results in systemic accumula-
tion of the noxious TP substrates thymidine and deoxyuridine. Gene therapy using either a lentiviral
vector or adeno-associated vector (AAV) has proven to be a feasible strategy, as both vectors restore
biochemical homeostasis in a murine model of the disease. This study shows that the effect of an AAV
containing the TYMP coding sequence transcriptionally targeted to the liver persists long term in mice.
Although the vector copy number was diluted and AAV-mediated liver TP activity eventually reduced or
lost after 21 months at the lowest vector doses, the effect was sustained (with a negligible decrease in TP
activity) and fully effective on nucleoside homeostasis for at least 21 months at a dose of 2 ·1012 vg/kg.
Macroscopic visual inspection of the animals’ organs at completion of the study showed no adverse effects
associated with the treatment. These results further support the feasibility of gene therapy for MNGIE.
Keywords: AAV, liver/metabolic, MNGIE, thymidine phosphorylase, mitochondria
INTRODUCTION
MITOCHONDRIAL NEUROGASTROINTESTINAL encephalo-
myopathy (MNGIE) is a mitochondrial disorder
caused by autosomal recessive mutations in the
nuclear gene TYMP, which encodes the cytosolic
enzyme thymidine phosphorylase (TP).1–3 MNGIE
patients lack TP activity, and this deficit leads to
systemic accumulation of TP substrates, the nucle-
osides thymidine (dThd) and deoxyuridine (dUrd),
which are precursors of the salvage pathway of
deoxyribonucleoside triphosphates (dNTPs), used
for DNA synthesis. This expanded nucleoside con-
centration changes the mitochondrial dNTP pool
and interferes with proper mitochondrial DNA
(mtDNA) replication. As a result of the dNTP
imbalance, MNGIE patients develop mtDNA de-
pletion, multiple deletions, and point mutations
in certain tissues, which leads to mitochondrial
dysfunction4,5 (see Supplementary Fig. S1; Sup-
plementary Data are available online at www
.liebertpub.com/hum). MNGIE is a fatal disease,
clinically characterized by gastrointestinal dys-
motility, progressive external ophthalmoplegia,
peripheral neuropathy, diffuse leukoencephalo-
pathy on brain magnetic resonance imaging, and
mitochondrial dysfunction. The average age of dis-
ease onset is 18 years, but most patients experience
their first symptoms in childhood. The condition
progressively degenerates until death ensues, usu-
ally due to the gastrointestinal complications, at a
mean age of 37 years.6
All the hitherto proposed therapeutic approaches
for MNGIE have been focused on reducing dThd and
dUrd concentrations to normal levels. The systemic
*Correspondence: Dr. Ramon Martı´, Research Group on Neuromuscular and Mitochondrial Diseases, Vall d’Hebron Research Institute, Pg Vall d’Hebron 119, 08035
Barcelona, Catalonia, Spain. E-mail: ramon.marti@vhir.org
HUMAN GENE THERAPY, VOLUME X NUMBER X DOI: 10.1089/hum.2017.133 j 1ª 2017 by Mary Ann Liebert, Inc.
D
ow
nl
oa
de
d 
by
 C
am
br
id
ge
 U
ni
ve
rs
ity
-a
dd
en
br
oo
ke
's 
H
os
pi
ta
l f
ro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
09
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
overload of these two compounds is the actual bio-
chemical cause of the disease. The noxious effect of
dThd excess on mtDNA replication has been dem-
onstrated in different in vitroand in vivomodels,7–10
and therefore these constitute good biomarkers to
predict the evolution of the disease. Only treatments
that provide a permanent biochemical correction
result in clinical improvement. Allogeneic hemato-
poietic stem-cell transplantation (alloHSCT) is the
most widely used therapy for MNGIE, as it has
proven to be effective in several patients; reduc-
tion of dThd and dUrd levels was associated with
clinical stabilization or improvement in MNGIE
patients treated with alloHSCT.11–13 In two recent
reports, orthotopic liver transplantation was also
successfully used to treat MNGIE.14,15 The ratio-
nale for these strategies is that both hematopoietic
and liver tissue show high TP activity in humans.
Therefore, engrafted donor tissue clears the dThd
and dUrd excess in recipients. However, both of
these options are invasive therapies and require
compatible donors, and, in the case of alloHSCT, the
procedure is associated with high mortality and
morbidity rates in MNGIE patients.12
Previously, it was proposed that gene therapy,
involving introduction of a functional copy of the
human TYMP coding sequence (hcTYMP) into
MNGIE patients’ cells, could be a noninvasive al-
ternative therapy that additionally would not re-
quire donor tissue. The existence of a murine model
of the disease16 has allowed this approach to be
tested preclinically. Although this animal model
does not recapitulate the clinical phenotype of the
disease, probably due to the short life expectancy of
mice, in combination with some differences in
deoxynulceoside metabolism between mice and hu-
mans, it reproduces the biochemical imbalances
observed in MNGIE patients, thus constituting a
useful tool to investigate the effects of experimental
therapies on the biomarkers of this disorder, that is,
the systemic levels of dThd and dUrd.
Using this animal model, the feasibility of gene
therapy was demonstrated using lentiviral vec-
tors targeting the hematopoietic system. Syngeneic
transplantation of transduced hematopoietic pro-
genitors into the Tymp/Upp1–/– double knockout
(KO) MNGIE model was able to correct the bio-
chemical derangement occurring in the disease.17
However, on long-term follow-up of treated mice,
survival was low due to the transplantation proce-
dure, which included total body irradiation of re-
cipient animals before progenitor cell infusion.18 An
alternative approach, using an adeno-associated vi-
rus (AAV) vector targeting the liver, also prevented
biochemical imbalances in mice. Intravenous ad-
ministration of the AAV vector containing hcTYMP
at doses as low as 2·1011 genome copies/kg led to a
permanent reduction in systemic dThd and dUrd
levels to normal values in about 50% of treated mice,
and higher doses reduced nucleoside levels in vir-
tually all treated mice.19 This study reports that the
therapeutic effect achieved with the AAV vector
persists throughout the life of the murine model
with no signs of adverse effects.
MATERIALS AND METHODS
Vector construction, production, and titration
The AAV2/8 vector containing hcTYMP under
the control of the tyroxine-binding globulin (TBG)
promoter was constructed, produced by triple
transfection of 293 cells, and titrated by quantita-
tive polymerase chain reaction (qPCR) and dot blot
analysis, as indicated in a previous study.19
Animal procedures
All animal procedures were performed using
protocols approved by the authors’ Institutional
Review Board and committee on animal care and
use. Eight- to 12-week-old Tymp/Upp1-/- mice16
were treated with a single intravenous injection
(tail vein) of AAV2/8-TBG-hcTYMP. Three groups
of animals were treated with three different doses:
2 ·1011, 1012, and 2· 1012 vector genomes (vg)/kg.
Blood samples (EDTA) were collected from the sa-
phenous vein 2 weeks before treatment and every
2–4 weeks after treatment, starting from week 1
and continuing for 28 weeks. Additional blood
samples were collected 65, 75, 80, and 88 weeks
after treatment. All the animals included in this
study were males, except a subgroup of female mice
used for the study on the influence of sex on the
effect of the treatment.
When mice showed signs of pain, suffering, dis-
tress, or lasting harm, they were euthanized before
the planned end of the study for humanitarian
reasons, according to the following endpoint rule
based on a scoring system included in the Euro-
pean Directive 2010/63/UE (Annex III 3.1 b). The
parameters that were monitored were body weight,
body condition, external appearance, and behav-
ior. Each parameter was scored from 0 to 3 based
on different indicators, and euthanasia was prac-
ticed in those mice whose score reached 3 in a
single parameter or 5 in the sum of the different
parameters.
TP activity and nucleoside determination
Plasma dThd and dUrd concentrations were
analyzed by high-performance liquid chromatog-
2 TORRES-TORRONTERAS ET AL.
D
ow
nl
oa
de
d 
by
 C
am
br
id
ge
 U
ni
ve
rs
ity
-a
dd
en
br
oo
ke
's 
H
os
pi
ta
l f
ro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
09
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
raphy with ultraviolet detection, as previously
described.17 TP activity and tissue nucleoside
concentrations were measured in mice 34 weeks
after treatment and in untreated, age-matched
mice. After killing the mice by cervical disloca-
tion, tissues were collected and immediately fro-
zen in liquid nitrogen and stored at -80C until
analysis. Frozen samples were homogenized in
lysis buffer (50 mM of Tris-HCl, pH 7.2, 10 mL/L
of Triton X-100, 2 mM of phenylmethylsulfonyl
fluoride, 0.2 mL/L of 2-mercaptoethanol) in a Potter
homogenizer. The homogenates were centrifuged at
20,000 g for 30 min at 4C, and supernatants were
separated into two aliquots. As described elsewhere,
one aliquot was used for protein determination20
and TP activity determination.21 The other aliquot
was frozen and later used to measure nucleosides
by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS). To prevent in vitro
degradation of dThd and dUrd during the ho-
mogenization procedure, for samples with TP ac-
tivities >100 nmol Thy/h/mg prot, a second piece
of tissue was homogenized in the presence of
100lM of 5-bromouracil (TP inhibitor) for the de-
termination of these nucleosides. Thawed superna-
tants were centrifuged at 20,000 g for 10 min at 4C
to eliminate any remaining particles, and clean su-
pernatants were deproteinized by ultrafiltration
(10 kDa Amicon Ultra filters; Merck Millipore, Bill-
erica, MA) at 14,000 g for 30 min at 4C. Five mi-
croliters of deproteinized homogenate were injected
into an Acquity UPLC-MS/MS instrument (Acquity
UPLC-Xevo TQ Mass Spectrometer; Waters, Mil-
ford, MA) using an Acquity UPLC BEH C18 column
(100·2.1 mm, 130 A˚ pore, 1.7lm particle; Waters).
The components of the sample were resolved and
detected, as previously described.19 Calibration
curves made with aqueous standards were pro-
cessed in parallel, and concentrations were ob-
tained from interpolation of the peak areas.
Vector copy number
DNA was extracted from liver with the QIAamp
DNA mini kit (Qiagen, Hilden, Germany). Detection
and quantification of vector genome copies per cell
was performed by quantitative PCR (qPCR) in the
ABI PRISM 7900 sequence detection system (Ap-
plied Biosystems, Foster City, CA). hcTYMP DNA
was quantified using the pre-designed TaqMan MGB
gene expression assay Hs00157317_m1 (Applied
Biosystems), and was referred to the single copy
nuclear gene Ang1 using the predesigned TaqMan
MGB gene expression assay Mm00833184_s1
(Applied Biosystems). The quantifications were
based on a standard curve prepared with different
dilutions of vectors containing hcTYMP DNA or a
specific region of the Ang1 gene.
Liver mitochondrial dNTP quantification
Liver mitochondria were isolated, as previously
described.8 Isolated mitochondria (0.5 mg of protein)
were treated with trichloroacetic acid (final concen-
tration 0.5 M) and centrifuged at 20,000 g for 5 min
at 4C. Supernatants were neutralized with 1.5
volumes of 0.5 M tri-N-octylamine in Freon (1,1,2-
trichlorotrifluoroethane) and centrifuged for 10 min
at 10,000gat 4C. Half the aqueous upper phase was
recovered and dried under a speed vacuum. Dry
dNTP extracts were dissolved in 40lL of 40 mM
Tris-HCl (pH 7.4) and stored at -80C until mea-
surement. For mitochondrial dNTP quantification,
the previously described polymerase-based assay8
was used with some modifications. Briefly, 10lL of
reaction mixture contained 5lL of dNTP extract in
40 mM of Tris-HCl (pH 7.4), 10 mM of MgCl2, 5 mM
of dithiothreitol, 0.25lM of oligoprimer, 0.75lM of
[8-3H]dATP, 12–21 Ci/mmol, and 0.25 units of Se-
quencing Taq DNA Polymerase (Bioron, Newtown
Square, PA). Reaction mixtures with aqueous dNTP
standards were processed in parallel. After incuba-
tion at 48C for 60 min, 9lL of the mix was spotted
onto one position of a DEAE Filtermat glass fiber
filter (PerkinElmer, Waltham, MA) and left to dry.
The filters were washed six times for 10 min with
5% Na2HPO4, once with water, and once with abso-
lute ethanol, and left to dry again. The filter was
covered with a Melt-on Scintillator sheet (Perki-
nElmer), and the retained radioactivity was deter-
mined by scintillation counting in a MicroBeta2
Microplate counter (PerkinElmer). dNTP amounts
were calculated from interpolation on thecalibration
curves. To ensure the reliability of the results, trip-
licates of two different dilutions of each dNTP ex-
tract (usually 1:3 and 1:10 water-diluted) were
processed in each independent experiment.
Statistical analysis
Statistical analyses were performed with Graph-
Pad Prism 5 software (GraphPad Software, Inc., La
Jolla, CA). The tests used are indicated in the figure
legends. For statistical purposes, undetectable val-
ues were considered as zero.
RESULTS
Treatment with AAV2/8-TBG-hcTYMP
provides a dose-dependent, permanent
nucleoside reduction
Blood samples were collected 2 weeks before
treatment (baseline values) and at several time
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points over 88 weeks after treatment to measure
nucleoside levels (Fig. 1). As was observed in a
short-term study with the same vector,19 the lowest
dose (2 ·1011 vg/kg) progressively reduced plasma
dThd and dUrd concentrations, which reached
normal levels 5 weeks after injection in most mice.
However, this positive effect was gradually lost in
all mice treated with this dose, and plasma dThd
and dUrd concentrations returned to KO levels at
the end of the study (88 weeks after treatment).
Higher doses (1012 and 2· 1012 vg/kg) produced
faster reductions in plasma nucleoside concentra-
tions, which reached wild-type (wt) levels or below
in all mice 1 week after vector injection. The effect
was maintained over the entire monitoring time, al-
though there was a slight rebound at the last analysis
(88 weeks) with the intermediate dose (1012 vg/kg).
Nonetheless, nucleoside levels in three of four mice
treated with the intermediate dose remained within
the wt range at that time.
Previous AAV studies in MNGIE have been per-
formed in male mice, as sex-biased AAV transduc-
tion efficiency has been observed in rodents (higher
in male mice than female mice).22 Therefore, the
study tested whether the treatment was also effec-
tive in females using two vector doses: 1012 and
2·1012 vg/kg. Although the small size of the sam-
ple would have compromised a reliable statistical
analysis of the data, inspection of the results sug-
gests that the vector was effective in reducing
systemic nucleoside levels in females, although
the effect was quantitatively less pronounced than
in males (Fig. 2). At 5 weeks following treatment,
circulating dThd concentrations in female mice
were lowered to wt levels with both doses (three of
four mice for each dose). This reduction was
maintained in females 75 weeks after treatment,
but dThd levels persisted within the wt range in
only one of three mice (1012 vg/kg) and two of four
mice (2 · 1012 vg/kg). In addition, there were re-
ductions in plasma dUrd levels (data not shown).
Parallel experiments conducted in male mice
showed similar results, but nucleoside reductions
were slightly greater in males than females.
AAV treatment restores dNTP balance
in liver mitochondria
At 96 weeks of age, untreated KO mice showed
significantly higher liver dThd and dUrd levels
than those of their wt counterparts (Fig. 3), find-
ings consistent with the previously reported results
for younger animals (42 weeks).17 These increases
were found to be significantly lowered in a dose-
dependent manner by treatment with the vector,
given at 8 weeks of age. At a vector dose of 2·1011
vg/kg, nucleoside levels in the liver had decreased
to wt values, and at higher doses, nucleosides had
dropped to below normal values.
Figure 1. Plasma thymidine (dThd) and deoxyuridine (dUrd) monitoring. dThd (a) and dUrd (b) concentrations in plasma obtained from untreated (n= 5) and
adeno-associated virus (AAV)-treated knockout (KO) mice (n= 6 for 2· 1011 and 1012 vector genomes [vg]/kg, and n = 5 for 2· 1012 vg/kg) over 88 weeks after
treatment (time 0). Gray area indicates the plasma dThd and dUrd concentration range in wild-type (wt) mice (n= 11). To facilitate matching the results of each
mouse between different figures, the same symbol identifies a particular mouse in Figs. 1, 3, and 4.
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Nucleosides are dNTP precursors within the sal-
vage pathway. As a consequence of this biochemi-
cal linkage, dThd and dUrd overload causes a
deoxythymidine triphosphate (dTTP) increase
and secondary deoxycytidine triphosphate (dCTP)
decrease in mitochondria of some tissues, including
the liver, and so on.8,18,19,23 These imbalances were
partially or totally prevented by the treatment.
Mitochondrial dCTP levels increased at all vector
doses tested, whereas the mitochondrial dTTP
increase was prevented, with reductions down to
wt levels or below at doses of 1012 and 2 · 1012 vg/
kg. dTTP remained unchanged at the lowest dose
of 2 · 1011 vg/kg (Fig. 3). Mitochondrial deoxy-
guanosine triphosphate (dGTP) levels did not
change with the treatment. dATP levels could not
be measured in liver mitochondria because the
values obtained were below the lower limit of
quantification.
Transgene copy number is diluted over time
Quantitative PCR analysis of DNA in the liver
of mice treated with the AAV2/8-TBG-hcTYMP
vector showed a small but noticeable dilution of
the vector genomes per cell over time (Fig. 4). At
the lowest vector dose, vector copy number per cell
was already negligible at 8 months after treat-
ment. At the two higher doses, vector copy number
8 months after treatment ranged from 0.1 to
1.8 vg/cell in 10 of 11 treated mice (median 0.35
and 0.46 vg/cell at doses of 1012 and 2 · 1012 vg/kg,
respectively). At 21 months after treatment, vec-
tor copy number had decreased (median 0.04 and
0.32 vg/cell at 1012 and 2 · 1012 vg/kg, respective-
Figure 2. Plasma dThd clearance in male versus female mice. Plasma dThd concentrations in male and female KO mice 5 and 75 weeks after treatment.
Doses are indicated on the x-axis (vg/kg). Horizontal lines represent medians. Gray areas indicate the plasma dThd concentration range in wt female (n = 8) and
male (n= 11) mice.
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ly). This loss of vector copy number correlated
with partial loss of TP activity over time. Eight
months after treatment, KO mice gained TP ac-
tivity in the liver in a dose-dependent manner,
reaching wt values in two of six mice treated with
the lowest dose, and approximate values of 600 to
1,000 nmol/h/mg of protein in mice treated with
higher doses. Thirteen months later (21 months
after treatment), TP activity had been lost in all
mice treated with the lowest dose (consistent with
the systemic nucleoside rebound observed in this
group; Fig. 1), and reduced in those treated with
the higher doses. It should be noted, however, that
in most mice treated with higher doses (seven of
eight) TP activities were maintained between 200
and 800 nmol/h/mg prot (fourfold increased or
higher compared to wt values) at 21 months. The
correlation between vector copy number per cell
and TP activity in treated mice was statistically
significant ( p < 0.0001).
Treatment with AAV2/8-TBG-hcTYMP did
not increase tumorigenesis or mortality rates
To investigate whether survival was affected in
treated mice, mortality was followed up to the end of
the study (96 weeks) in wt untreated KO and AAV-
treated KO mice at all doses (Fig. 5 and Supple-
mentary Table S1). Kaplan–Meyer analysis showed
that median survival was not significantly different
between wt and untreated KO mice (although a
lower percentage of KO mice than wt mice were
alive at the end of the study). The treatment did not
affect survival of the animals at any dose, either
positively or negatively (i.e., median survival in
Figure 3. Nucleoside concentrations and mitochondrial nucleotide levels in the liver after long-term transgene expression. (a) dThd and dUrd concentrations
in wt (n= 5), untreated KO (n= 9), and AAV-treated KO mice with 2· 1011 (n= 5), 1012 (n = 4), and 2· 1012 vg/kg (n= 5) 21 months (88 weeks) after treatment.
(b) Mitochondrial deoxythymidine triphosphate (dTTP), deoxycytidine triphosphate (dCTP), and deoxyguanosine triphosphate levels in wt (n= 7), untreated KO
(n= 9), and AAV-treated KO mice with 2 · 1011 (n= 5), 1012 (n = 4), and 2· 1012 vg/kg (n= 5) 21 months after treatment. Horizontal lines represent medians. Gray
underlined asterisks indicate statistical differences compared to untreated KO mice (*p< 0.05; **p < 0.01, Mann-Whitney U-test). The group of mice treated
with the higher vector dose had lower dTTP levels ( p < 0.05) and higher dCTP levels ( p < 0.05) than those of wt mice. To facilitate matching the results of each
mouse between different figures, the same symbol identifies a particular mouse in Figs. 1, 3, and 4.
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mice treated with each vector dose did not signifi-
cantly differ from that of untreated KO mice).
To detect the development of tumors, the organs
of a group of mice killed at the end of the study or
following the euthanasia recommendation accord-
ing to the endpoint rule were carefully examined
(see Materials and Methods). This analysis only
included macroscopic visualization of organs at
necropsies, without organ dissection or microscopic
analyses. The findings of this examination are
summarized in Table 1. The limited number of
treated animals examined and the variability of the
tumors found precludes definitive conclusions, but
the incidence of liver tumors (target tissue of the
study) was not higher in AAV-treated KO mice
than in wt or untreated KO mice in the overall data
analysis.
DISCUSSION
MNGIE is caused by systemic accumulation of
dThd and dUrd, which interfere with mtDNA repli-
cation and maintenance in certain tissues that are
particularly susceptible to injury by increased nu-
cleoside levels. Consequently, current MNGIE ther-
apies have focused on preventing dThd and dUrd
overload in several target tissues, as has been re-
viewed.24 Past experience has shown that MNGIE
therapies are effective only when the systemic nu-
cleoside reduction is sustained over time,12–15 and
preclinical evidence indicates that this objective can
Figure 4. Vector genomes and thymidine phosphorylase (TP) activity in
the liver. Quantitative polymerase chain reaction–assessed AAV genome
copies in the liver from treated KO mice using a human TYMP cDNA probe
(a), and TP activity in the liver of wt, untreated, and treated KO mice 8 and
21 months (88 weeks) after treatment (b). The number of animals in con-
secutive groups of panel (a) are, from left to right, n = 6, 5, 6, 4, 5, and 5. The
number of animals in consecutive groups of panel (b) are, from left to right,
n = 6, 3, 4, 11, 6, 5, 6, 4, 5, and 5. Horizontal lines represent medians. Doses
are indicated on the x-axis (vg/kg). Asterisks indicate statistical differences
between groups (*p < 0.05, Mann-Whitney U-test). To facilitate matching
the results of each mouse between different figures, the same symbol
identifies a particular mouse in Figs. 1, 3, and 4.
Figure 5. Survival curve. Kaplan–Meier survival representation of wt,
untreated KO, and treated KO mice.
Table 1. Tumorigenesis study
Group/dose
Total
studied
Number of
mice with
tumorsa Tumors detected
WT 16 3 (19%) 1 (spleen, liver, and lung), 2 (spleen)
KO 30 6 (20%) 2 (lung), 2 (small intestine),
1 (liver), 1 (spleen, kidney, and liver)
2· 1011 vg/kg 6 2 (33%) 1 (lung), 1 (small intestine and lung)
1012 vg/kg 6 1 (17%) 1 (lung)
2· 1012 vg/kg 5 2 (40%) 1 (liver), 1 (small intestine and lung)
Specific subsets of animals belonging to different groups were selected
at the beginning of the study to investigate the occurrence of tumors at the
end of the study (when they were killed at the end of the study, or before
the end of the study following the endpoint rule for humanitarian reasons).
aTumors found in necropsies at the end of the study (age 96 weeks) or
after euthanasia.
wt, wild type; KO, knockout; vg, vector genomes.
LONG-TERM AAV GENE THERAPY FOR MNGIE 7
D
ow
nl
oa
de
d 
by
 C
am
br
id
ge
 U
ni
ve
rs
ity
-a
dd
en
br
oo
ke
's 
H
os
pi
ta
l f
ro
m
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
4/
09
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
be achieved using gene therapy. Gene therapy strat-
egies based on a lentiviral vector targeting the he-
matopoietic system or an AAV targeting the liver
have shown biochemical efficacy in a murine model
of the disease.17–19 In the case of hematopoietic tis-
sue transduced with a lentiviral vector, the effect is
maintained over the life of treated mice, but the pro-
cedure itself is associated with a reduction in the
animals’ life span. The present study reports that
treatment with AAV2/8-TBG-hcTYMP targeting the
liver in a murine model also provides a permanent
biochemical correction, but without adverse effects.
A previous report found that various doses of this
vector lowered dThd and dUrd in the blood and
several tissues for at least 34 weeks after treat-
ment.19 In this study, it was observed that the bio-
chemical correction is fully maintained over the
entire life of most mice treated with 1012 vg/kg and
all mice treated with 2·1012 vg/kg. At the lowest
dose tested (2·1011 vg/kg), the biochemical effect
persisted for the first 30 weeks (consistent with the
results of a previous study) but was lost thereafter
in all animals. This loss of effect coincided and cor-
related with a reduction in vector genomes and TP
activity in the liver. Some dilution effect was ex-
pected for AAVs because they mainly remain as
episomes in the nucleus of transduced cells.25 The
average hepatocyte turnover time in uninjured liver
of adult mice is 150 days.26 Therefore, an 85% vg/cell
reduction would be expected in 350 days (between 8
and 21 months, the times at which this endpoint
was assessed). Accurate quantification of this re-
duction was difficult in this study because vector
copy number in the liver cannot be assessed twice in
the same mouse (liver biopsies stimulate hepatocyte
proliferation, leading to overestimation of the dilu-
tion effect), and the wide dispersion of copy number
data (illustrated in Fig. 4a) makes precise copy
number assessment difficult in different mice at
different times. However, the data seem to indicate
that the reductions were less marked than was ex-
pected, especially for the highest vector dose. At the
lowest dose, vector copy number was already barely
detectable 8 months after treatment.
The dilution effect was also less pronounced than
expected when assessed in terms of liver TP activity.
Among the factors that could account for retention
of copy number and TP activity, a small but relevant
proportion of AAV may have been integrated in the
genome of hepatocytes25 and replicated in parallel
with cell division. A dilution effect is not expected
(and is not observed) when a lentiviral vector is used
because these vectors integrate in the genome and
are not diluted when cells divide.17,18 In humans,
the turnover time of mature hepatocytes in a fully
developed, uninjured liver ranges from 200 to
300 days.27 Hence, dilution of the AAV therapeutic
effect along time is also expected. Data from the
single related clinical trial reported to date, in which
hemophilia B was treated with a scAAV8 targeting
the liver, have shown that factor IX expression
(product of the transgene in this clinical study) is
stable for >5 years.28,29 These results indicate that
the dilution effect in humans may be slow enough to
be undetectable in this moderate time frame. How-
ever, huge efforts in the field of AAV gene therapy
are aimed at developing new capsid vectors com-
patible in terms of immunogenicity with a second
vector infusion in order to overcome issues derived
from the long-term dilution effect.
An impact of sex on liver transduction with
AAVs is well recognized in the literature, with
greater transduction efficiency reported in males
than females.22,30–33 Previous studies in other
murine models have proposed various explana-
tions for the higher transgenic expression in male
mice, such as an interaction between the AAV ITR
and testosterone-dependent host nuclear regula-
tory proteins22 and contact between AAV vectors
and inhibitory molecules present in the blood.30
Only male mice were used in the authors’ first
study on AAV,19 but the experience was expanded
to both male and female mice in the present study.
The results indicate that AAV treatment is effective
in both sexes, although the reduction in plasma
nucleosides is more pronounced in males than it is
in females. Since a single intravenous injection was
used, both the above-mentioned explanations could
account for the differences between sexes. Never-
theless, it is important to note that evidence from
studies in nonhuman primates and patients suffices
to affirm that this difference only pertains to ro-
dents.34 Therefore, the sex-related differences ob-
served here are not relevant when considering the
use of this approach to treat MNGIE patients.
The liver is an advantageous target organ for
gene correction in MNGIE patients, not only be-
cause of its immunological tolerance, which limits
the immune response against the vector capsid and
TP protein, but also because it is one of the richest
organs in TP activity in humans,21,35 and a par-
ticularly suitable tissue to host systemic clearance
of metabolites.
TP activity was found to be 3- to 14-fold higher in
the murine model than in wt mice at 21 months after
treatment with the highest vector dose. This high
activity resulted in excessively reduced nucleoside
levels in the blood, which could be a concern, as this
could lead to dTTP depletion in quiescent hepato-
cytes. Since de novo dTTP synthesis is cell-cycle de-
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pendent and downregulated in nondividing cells,
hepatocyte dTTP levels mainly depend on the sal-
vage pathway and would be affected by abnormally
low dThd levels. It was found that the dThd over-
reduction observed at the highest vector dose was
associated with slight mitochondrial depletion of
dTTP (below wt values) and expansion of dCTP
(above wt values). Hence, it is concluded that the
dose-dependent effect on blood nucleoside levels is
reflected downstream in the mitochondrial salvage
pathway by inducing a dose-dependent dTTP re-
duction and dCTP expansion, although the above-
mentioned over-corrections point out the difficulty of
finely adjusting the vector dose to reach the wt dNTP
levels. Of note, 21 months after treatment with the
lowest vector dose, dTTP remained at KO levels, as
also occurred with blood dThd levels in the same
group and at the same time. By contrast, liver
dThd levels were normal. The reason for these in-
consistent findings is unknown, and some bias
derived from the low number of available samples
from old animals cannot be ruled out. In contrast to
the changes observed in pyrimidine deoxynucleo-
tides, mitochondrial dGTP levels were not affected
by the treatment.
The effect of the treatment on nucleoside and
mitochondrial nucleotide levels underlines the im-
portance of adjusting the vector dose in patients so
that excessive TP activity will not change the dNTP
pool beyond the objectives of the treatment. How-
ever, it is unlikely that the doses tested here will
result in liver TP activities higher than normal in
humans. Liver TP activities in mice treated with the
highest dose were still around four times lower than
the normal values in human liver.21 Even consid-
ering that we were testing a human gene under a
human promoter in mice, this observation suggests
that if use of this vector were translated to patients,
the concern would not be TYMP overexpression but
instead the inability to reach TP levels high enough
to normalize systemic nucleoside concentrations.
The fact that AAV8 transduction efficiency in ro-
dents is higher than in humans36,37 reinforces this
viewpoint. Which is the best serotype to target hu-
man liver is a relevant and controversial issue.
Some studies in humanized mouse models suggest
that AAV3-derived engineered serotypes infected
human cells much more efficiently than AAV8,36–38
while other studies do not support this conclusion,
showing instead similar efficiencies.39,40
There is considerable controversy regarding the
oncogenic potential of AAV use in gene therapy,
and several studies have been reported with rather
conflicting results. In one experimental study in
mice, hepatocellular carcinoma developed after
injection of a therapeutic AAV due to integration of
the vector into a genomic region encoding numerous
regulatory RNAs.41 Furthermore, AAV2 infection
has been associated with oncogenic insertional mu-
tagenesis in human hepatocellular carcinoma.42
However, other authors have found no associated
increase in tumorigenesis with AAV use in mice,43,44
and a recent study reported an absence of hepatic
genotoxicity in relation to systemic administration
of an AAV2/5 in nonhuman primates and acute in-
termittent porphyria patients.45 In another study,
random AAV integration in several loci, including
mtDNA, was reported,46,47 but the findings were
considered largely artefactual by others.48 These
discrepancies have been attributed to differing ex-
perimental conditions.49 It has also been hypothe-
sized that the enhancer–promoter encoded by the
vector can influence its genotoxicity, as it can lead to
overexpression of the genes located close to the in-
tegration site.49 This study used the TBG promoter,
which has been associated with insertional muta-
genesis.49 Nonetheless, in this study, the incidence
of liver tumors in AAV-treated mice was similar to
the spontaneous hepatocellular carcinoma inci-
dence in wt and untreated KO mice and to the
rates described in other studies.49–51 The small
size of the cohort of treated mice does not allow an
increased incidence of tumors to be ruled out. A
dedicated study with higher numbers of mice is
needed to address this potential issue, but this
objective is beyond the scope of this study. Of note,
this study treated adult mice and not newborns,
and the doses administered were 50 times lower
than those resulting in tumorigenesis.49 Thus, at
the doses used, it seems that the genotoxic poten-
tial of the vector is low, but the therapeutic benefit
is retained. To verify the safety of the vector fur-
ther, a Kaplan–Meier analysis was performed,
which found no association of the treatment with
higher mortality in this study.
This extended study provides further evidence
that gene therapy using an AAV targeting the liver
is a feasible therapeutic option for MNGIE treat-
ment. Among the variables that can influence the
success of this therapy, selection of the appropriate
vector dose is one of the most important to be con-
sidered. A vector dose range is described that al-
lows long-term correction and did not show adverse
effects derived from transgene overexpression or
vector genotoxicity, although more detailed and
expanded studies are needed to ensure the safety of
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the treatment. This information may be of value for
designing and implementing future clinical trials
with MNGIE patients.
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